1、203 2 N k b B 7 t PA aPAI J S 1992 25 260 3 D 7 5 h s 1 J S 1996 29 5 376 4 Matsumori A Takano H Obata JE et al Circulating hepatocyte growth factor as a diagnostic marker of thrombus formation in patients with cere bral infarction J Circ J 2002 66 2 216 5 Tardy B Tardy Poncet B Viallon A D dimer le
2、vels in patients with sus pected acute cerebral venous thrombosis J Am J Med 2002 113 3 238 6 Lupu F Bergonzell GE Heim DA et al Localication and production of plasminogen activator inhibitor21 in human healthy and atherosclerot i carteries J Arterioscler Thromb 1993 13 1090 7 Altes A Abellan MT Mat
3、eo J et al Hemostatic disturbances in acuteis chemicstrokes a study of86 patients J ActaHaematol 1995 94 10 8 Heinrich J Schonfeld R Association of coagulation fibrinolysis and a cute phasewith atherosclerosis in coronary and peripheralarteries andthose ar teries supplying the brain J Thromb Haemost
4、 1995 371 9 y null D 8 Z E h J D 1997 20 3 169 l 2008 04 07 Y T c I 1007 4287 2009 04 0506 04 A 1 FCCP F 8 5 i l 杜null 娟1 郭嘉隆1 李宗树2 毕黎琦1 1null v q D A h S 130033 2null 8 D 5 u K 1 null 1 F t F 8 FCCP F 8 b A 1 RA h S K 5 S M 1 b Z Enull 87 RA s Y FCCP F 8 aIgG RF aIgM RF aIgA RF i c n 1 a e 1 a h DA
5、S 28 5 S b s FCCP F 8 5 S M b FCCP F 8 5 S S K 1 b Tnull 87 RA FCCP F 8 54 62 1 RF 56 64 4 b FCCP F 8 F n 1 a e 1 A F P 0 000 0null000 DAS 28 s A F P 0null000 X L C S K P 0 000 b b FCCP F 8 n 1 a e 1 aDAS 28 s A M 1 r 0 601 P 0null000 r 0 574 P 0 000 r 0 698 P 0 000 7 ESR M 1 r 0 322 P 0 018 bIgG RF
6、 aIgA RF aIgM RF M 1 b62 RA i S K 71 3 25 S K 28 7 F W FCCP F 8 aIgA RF aESR s d 9 i l P 0 000 0 022 0null004 b X L s b FCCP F 8 s d 9 i l P 0 000 b null FCCP F 8 b n 1 a e 1 aDAS 28 S K M 1 V T N h S K 1 S b 1 o M F t F 8 1 A m s R593 22 D S M A Clinical significance and detection of ant i cyclic c
7、itrullinatedpeptide antibody in early rheumatoid arthritis null DU Juan GUO Jia long LI Zong shu et al Department of Rheumatology and Immunology China Japan Union Hospital of Jilin University Changchun 130033 China Abstract Objectivenull To compare theassociation of ant i cyclic ciryellinated peptid
8、e antibody ant i CCP and their serum lev els with disease activity score for 28 DAS 28 aswollen joint count SJC atender joint count TJC bone erosion in a cohort of pa tients with earlyrheumatoid arthritis RA Methods null Ant i CCP aIgG RF aIgM RF aIgA RFwere detected in 87 cases of early RA IgG RF a
9、IgM RF aIgA RF aESR and DAS 28were compared between patients with ant i CCP positive and negative and the correla tions amongthe level of ant i CCP and clinical manifestations alaboratoryfindings and bone erosion were analyzed Resultsnull From 87 early RA patients 62 1 were ant i CCP positive 64 4 w
10、ereRF positive ant i CCP positive patients presented with higher SJC P 0 000 and TJC P 0 000 and exhibited moreactivedisease expressed by higher DAS 28 p 0 000 and erosive disease was significantly higherthan ant i CCP negative patients The serum levels of ant i CCPshowed a significant correlation w
11、ith SJC P 0 000 aTJC P 0 000 and DAS 28 P 0 000 and weak correlation with ESR P 0 018 but there is no correlation with IgG RF aIgM RF and IgA RF 71 3 werepatients with erosivedisease Theserum levels of ant i CCP aIgA RF andESR wereof sta null506null Chin J Lab Diagn April 2009 Vol 13 No 4 tistical s
12、ignificancebetween patients with erosive disease and non erosivedisease The differenceof ant i CCP level in blood serum in different x ray periods except period null is of statistical significance Conclusionnull The presence of ant i CCP and theirserum levels is associated with SJC aTJC aDAS 28 and
13、bone erosion Ant i CCPcan beused as evaluation of disease activity and prediction of bone erosion Key words ant i cyclic citrullinated peptide antibody arthritis rheumatoid Chin J Lab Diagn 2009 13 0506 null null A 1 rheumatoid arthritis RA S 1 G L 5 V C aX L A y 0 rheumatoid factor RF S H X C 7RF s
14、 S RA b2000 MSchellekens 1 ELISA E A 1 b F t F 8 ant i cyclic citrullinated peptide ant i body FCCP F 8 i L FCCP F 8 RA s b FCCP F 8 1 RA N RA 5 M 1 2 f RA s F B s s F FCCP F 8 b RA h a S K 5 S M 1 V 7 FCCP F 8 RA 5 V C 1 5 T RA 4 G b 1null Z E 1 1 null 2006 M8 2007 M10 v q D A f S h 2 M RA 87 o 64
15、3 23 3 o h 1 q 1null3 b M 18 68 43 null 15 b h 12 2 M b S A h ACR 1987 M RA s S 3 i 2003 M x F A h 4 RA l h 12 2 M W i O P VDMARDs b l M a Y a n 1 a e 1 a z H W a q erythrocyte sed i mentation rate ESR a h DAS 28 a m 1 X L b mX L 1 h M s null null bnull M B d S K F null anull anull M B S K F b 1 2 n
16、ull k Z E 1 2 1null FCCP F 8 null FCCP F 8 k 4 SEUROIMMUN D L K 4 F Z S M v d s Y F S A 1 ml 10 nulll S A F 10 nulll b 100 nulll d b F d i 1 h b b A 4 Q b F100 nulll a S F IgG B d i 22null 30 min b b A 4 Q b F A100 nulll B d i 22null E 30 min b F A H M Q F100 nulll A B d b F A 60min S N o 405 nm 1 b
17、 s Y 5 S M a U S T S w L N p b FCCP F 8 i Tnull15 RU ml b 1 2 2null RF null RF k 4 Z o 3 K 4 S d s Y F 8 S 0 40 60 80 160 320 640 1280 2560 IU ml d z S e 1 ml b b 37null Q 1 5 h b l d A 8 A 4 Q 8 d b d F100 nulll S b b 37null Q 1 5 h b l d A 8 A 4 Q 8 d b d F100 nulll 5 z b b 37null Q 20 min b d F1
18、50 nulll A b S N 490 nm o 0 S 5 n b S S w L p IgG RF a IgM RF aIgA RF 1 c IU ml b I s Y 110 IU ml a 40 IU ml a 120 IU ml b 1 3null d 9 s SPSS 11 5 q d 9 s 9 nullx null s V U F 1 t F 1 Z s M W M 1 s Spearmannull s M 1 s 9 1 null2 P 0 05 s d 9 i l b 2null T 2 1null FCCP F 8 aRF RA 1 q 87 RA 54 FCCP 56
19、 RF q s Y 62 1 64 4 Z E W s d 9 i l P 0 845 b 42 48 3 RF a FCCP F 8 19 null507null S L null 2009 M4 null 13 null 4 21 8 RF a FCCP F 8 b RF RA 12 FCCP F 8 RF F38 7 b 2 2 null RA FCCP F 8 F F 5 S 1 87 RA FCCP F 8 F n 1 a e 1 A F P 0 000 0 000 DAS 28 s A F P 0null000 X L C S K 1 q A F CCP F 8 F P 0 000
20、 ESR F W s d 9 i l b n V1 b 2 3 null RA b FCCP F 8 5 S M 1 s b FCCP F 8 n 1 a e 1 aDAS 28 s A M 1 r 0 601 P 0null000 r 0 574 P 0 000 r 0 698 P 0 000 7 ESR M 1 r 0 322 P 0 018 z H W a bIgG RF aIgA RF aIgM RF M 1 b n V2 b V1 null RA FCCP F 8 F F 5 S 1 FCCP F 8 n 54 FCCP F 8 n 33 P n 1 15 94null 6 13 8
21、 55null 2 58 0 000 e 1 15 98null 6 78 8 67null 3 28 0 000 ESR mm 1 h 51 63null 20 41 44 0null 16 55 0 076 DAS 28 6 59null 0 87 5 61null 0 53 0 000 S K F75 8 24 2 0 000 null null FCCP F 8 F F 1 P 0 01 V2null RA FCCP 5 S M 1 s 5 S r P n 1 87 0 601 0 000 e 1 87 0 574 0 000 DAS 28 87 0 698 0 000 ESR 87
22、0 322 0 018 IgG RF 87 0 096 0 491 IgA RF 87 0 006 0 964 IgM RF 87 0 012 0 930 null null P 0 05 P 0 01 2 4null RA FCCP F 8 aRF s b S K M 1 87 RA S K F 62 71 3 d S K F 25 28 7 b S K F FCCP F 8 47 S K F 75 8 RF 43 S K F69 4 b d S K F FCCP F 8 7 d S K F 28 RF 13 d S K F52 b 6 19 FCCP F 8 RF RA 8 C S K b
23、 S K F d S K F W FCCP F 8 aIgA RF ESR s d 9 i l P 0 000 0 022 0 004 b n V3 b V3 null RA X L s F FCCP F 8 a RF s aESR 1 d S K F n 25 S K F n 62 P FCCP F 8 43 80null 61 94 165 30null 107 34 0 000 IgM RF 308 72null 552 57 254 47null 367 78 0 594 IgG RF 156 12null 88 82 167 44null 110 02 0 649 IgA RF 14
24、1 76null 37 76 172 87null 86 65 0 022 ESR 39 40null 17 67 52 53null 18 75 0 004 null null S K F d S K F 1 P 0 05 2 5null RA X L s b FCCP F 8 ESR 1 y Q RA h N 2 M Cnull X L V C b X L s b FCCP F 8 s d 9 i l null null null null Z s s A b 87 RA null null X L M ESR null M 1 s d 9 i l null null A null nul
25、l null W 1 s d 9 i l b n V4 b V4 null RA X L s b F CCP F 8 aESR 1 X L s FCCP RU ml ESR mm 1 h null 25 43 80null 61 94 39 40null 17 67 null 41 129 17null 99 52 50 12null 19 64 null 21 235 85null 86 20 null 57 24null 16 30 null null null 1 P 0 05 null null 1 P V C d b S RA h q 0 32 0 36 3 o h null508n
26、ull Chin J Lab Diagn April 2009 Vol 13 No 4 1 q 3null1 b V l 5 s 3 o 1 N M b 54 FCCP F 8 q 62 1 Biz zaro 4 s y V FCCP F 8 F s 0 B s F 8 b c F 8 s P t V B s F b V 71 3 RA h M C S K 4 U RA S K 3 q b X 5 V 50 RA h2 M C S K 1 8 N t V v RA O 3 h y 7 PRA y p m 1 X L 1 b Y V FCCP F 8 FCCP F 8 5 S 1 C FCCP
27、F 8 RA 1 n 1 e A 9 FCCP F 8 RA 1 A bDAS 28 s F W 1 A s 4 U h g B Pa padopoulos 5 Samanci 6 M b 7 s FCCP F 8 5 S 1 H C b FCCP F 8 DAS 28 n 1 e 1 A M 1 b 9 h f M 1 Papadopoulos I n y n 5 P VDMARDs 7 Papadopoulos B DMARD V FCCP F 8 M i O X V DMARDs 0 V P b FCCP F 8 b Q h null R A H A 1 L i Z J S L 2008
28、 12 1 137 3 Bizzaro N Mazzanti G TonuttiE et al Diagnostic accuracy ofthe antic itrulline antibody assay for rheumatoid arthritis J Clinical Chemistry 2001 47 61 1089 4 Arnett FC Edworthy SM Bloch DA et al The American Rheumatism Association 1987 criteria for the classification of rheumatoid arthrit
29、is J Arthritis Rheum 1988 31 315 5 Papadopoulos NG TsiaousisGZ Pavlitou TsiontsiA et al Does thePres ence of Ant iCCP Autoantibodies and Their Serum Levels Influence the Severity and Activity in Rheumatoid Arthritis Patients J Clin RevAller gy Immunol 2008 34 1 11 6 SamanciN Ozdem S AkbasH et al Dia
30、gnostic valueand clinical signif icanceof ant i CCP in patients with advanced rheumatoid arthritis J J NatlMed Assoc 2005 97 8 1120 7 del Val del Amo N Ibanez Bosch R Fito Manteca C et al Ant i cyclic citrullinated peptide antibody in rheumatoid arthritis relation with disease aggressiveness J Clin
31、Exp Rheumatol 2006 24 3 281 8 d l f F t F 8 A 1 h S K 1 J A h 2008 12 9 603 9 Berglin E JohanssonT Sundin U etal Radiologicaloutcomein rheuma toid arthritis is predicted by presence of antibodies against cyclic citrull i nated peptide before and at diseaseonset and by IgA RFat diseaseonset J Ann Rheum Dis 2006 65 4 453 l 2008 04 23 null509null S L null 2009 M4 null 13 null 4
